Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Megan Grudem"'
Autor:
Amanika Kumar, Bahaaeldin Youssef, Yi Lin, Martin J. Cannon, Geraldine V. Vijay, Michael P. Gustafson, Michael A. Strausbauch, Michael C. Deeds, Gretchen E. Glaser, Keith L. Knutson, Courtney L. Erskine, Mary L. Solseth, Matthew S. Block, Allan B. Dietz, Carrie L. Langstraat, Carolyn Klampe, Aminah Jatoi, Kevin D. Pavelko, Andrea E. Wahner-Hendrickson, Kimberly R. Kalli, Megan Grudem, Jacob B. Allred, S. John Weroha
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved survival, whereas regulatory T cells predict poorer survival. We previously developed a vaccine whereby patient-derived dendritic cells (DCs) are programmed to induce Th17 respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5d84e73fece13875a906875ca2492f
http://link.springer.com/article/10.1038/s41467-020-18962-z
http://link.springer.com/article/10.1038/s41467-020-18962-z
Autor:
Vonda Wall, Sara Klennert, Carolyn Klampe, Clarissa Polen-De, Sarah A. Kroc, Megan Grudem, Kandelaria M. Rumilla, Amanika Kumar, Myra J. Wick, Casey L. Swanson
Publikováno v:
Gynecologic Oncology. 162:S185-S186
Objectives: Women with epithelial ovarian cancer (EOC) who have a germline mutation, somatic mutation or are found to have homologous recombination deficiency (HRD) have been shown to have an improved survival with use of a PARP inhibitor after compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc41a5079339600651b8c86b2f2008c5
https://doi.org/10.1016/s0090-8258(21)00999-9
https://doi.org/10.1016/s0090-8258(21)00999-9
Publikováno v:
Journal of the Advanced Practitioner in Oncology
Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcde0295f7c1d1c91cf13a08044e6bcc
https://doi.org/10.6004/jadpro.2020.11.3.16
https://doi.org/10.6004/jadpro.2020.11.3.16
Autor:
Erin Deering, Deanne Smith, Alan P. Fields, Aminah Jatoi, Jose C. Villasboas, Pashtoon Murtaza Kasi, Matthew S. Block, Juliana Perez Botero, Aaron S. Mansfield, Angelina Tan, Travis J. Dockter, Scott H. Okuno, Megan Grudem
Publikováno v:
Supportive Care in Cancer. 25:833-838
Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. In a randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bbb3cbafb0438096a962792b2ec2211
https://doi.org/10.1007/s00520-016-3467-9
https://doi.org/10.1007/s00520-016-3467-9
Autor:
Jill Schimke, Carrie L. Langstraat, Andrea E. Wahner Hendrickson, Joel M. Reid, Aminah Jatoi, Svetomir N. Markovic, Gretchen E. Glaser, Carrie Strand, Wendy K. Nevala, Amanika Kumar, Carolyn Klampe, Vera J. Suman, Heidi D. Finnes, Matthew S. Block, Eleftheria Kalogera, Megan Grudem, Saravut J. Weroha
Publikováno v:
Journal of Clinical Oncology. 38:e18097-e18097
e18097 Background: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (NP) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of vascular-endothelial growth factor (VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa164887748fb0f083e8c7491711bced
https://doi.org/10.1200/jco.2020.38.15_suppl.e18097
https://doi.org/10.1200/jco.2020.38.15_suppl.e18097
Publikováno v:
The American journal of hospicepalliative care. 36(1)
Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4068f5092e97113adac02d659da11bcc
https://pubmed.ncbi.nlm.nih.gov/29983087
https://pubmed.ncbi.nlm.nih.gov/29983087
Autor:
Jennifer L. Ridgeway, Jessica L Mitchell, Megan Grudem, Carmen Radecki Breitkopf, Jennifer L Lee, Joseph H. Butterfield, Daniel S. Childs, S. John Weroha, Aminah Jatoi, David J. Bartlett, Sherry A. Looker
Publikováno v:
The American journal of hospicepalliative care. 35(11)
Objective: A growing number of cancer antineoplastic agents can cause life-threatening acute infusion reactions. Because previous studies have not studied these reactions from the perspective of patients, this study was undertaken with that objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9559a46810038fc9b550403a28c06dd
https://pubmed.ncbi.nlm.nih.gov/29724109
https://pubmed.ncbi.nlm.nih.gov/29724109
Autor:
Sherri Longenbach, S. John Weroha, Krishna Patel, Jamie N. Bakkum-Gamez, Matthew S. Block, Lance A. Mynderse, Vesna D. Garovic, Henry C. Pitot, Amanika Kumar, Aminah Jatoi, Megan Grudem
Publikováno v:
Psycho-Oncology. 25:605-609
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62d66b513ebe20e585d68aa77438be5b
https://doi.org/10.1002/pon.3889
https://doi.org/10.1002/pon.3889
Autor:
Megan Grudem, Nina Karlin, Andrea E. Wahner Hendrickson, Rachel Carlson, Carmen Radecki Breitkopf, Aminah Jatoi, Alan P. Fields, Matthew S. Block, Brigitte A. Barrette, Nathan R. Foster
Publikováno v:
Oncology. 88:208-213
Purpose: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with the protein kinase C iota (PKCι) inhibitor auranofin and (2) to understand patients' percepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95242d7b8f0bb45b3fca5400508f9fd6
https://doi.org/10.1159/000369257
https://doi.org/10.1159/000369257
Autor:
Sherri Longenbach, Jamie N. Bakkum-Gamez, Amanika Kumar, Megan Grudem, Michael G. Haddock, Nathan R. Foster, Sean C. Dowdy, Krishna Patel, Aminah Jatoi
Publikováno v:
Supportive Care in Cancer. 23:1303-1309
Hydronephrosis is a frequently observed but understudied complication in patients with cervical cancer. To better characterize hydronephrosis in cervical cancer patients, the current study sought (1) to describe hydronephrosis-associated morbidity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4669d7c4091e006043507fcaa6cffdf4
https://doi.org/10.1007/s00520-014-2482-y
https://doi.org/10.1007/s00520-014-2482-y